Can two factories make the same Parkinson's drug? a trial puts it to the test
NCT ID NCT07727785
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This trial investigates whether pramipexole tablets produced at two different manufacturing sites are processed identically by the body. Healthy volunteers aged 18 to 55 take both versions in a crossover design, and researchers compare drug levels in the blood. The goal is to confirm bioequivalence, which could ensure consistent medication quality regardless of where the drug is made.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pramipexole tablets (Sifrol® and Mirapex®)
- What this could lead to
- If the tablets are bioequivalent, it could confirm that manufacturing at either site produces the same medicine, supporting reliable supply.
- What could go wrong
- This is a small, early-phase study in healthy people, not patients. Results may not reflect real-world use or detect rare differences.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Humanpharmakologisches Zentrum Biberach
Biberach, 88397, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test